• ThromboGenics

    A committee of the European Medicines Agency has granted a positive opinion for a more convenient formulation of ocriplasmin (Jetrea), according to ThromboGenics.

    Already approved in the European Union for treating vitreomacular traction, ThromboGenics is seeking approval of a new formulation designed to eliminate the pre-injection dilution steps.

    “With this new formulation, it will be easier and more convenient for retina physicians to use this novel pharmacological option for the treatment of patients with vitreomacular traction,” said Dr. Patrik De Haes, CEO of ThromboGenics.

    ThromboGenics anticipates final approval from the European Commission in 2 to 3 months. Alcon, which commercializes ocriplasmin outside the United States, will launch the new formulation.